LT3412687T - Didžiųjų b ląstelių difuzinės limfomos gydymo būdai - Google Patents

Didžiųjų b ląstelių difuzinės limfomos gydymo būdai

Info

Publication number: LT3412687T
Authority: LT; Lithuania
Prior art keywords: methods; treating dlbcl; dlbcl; treating
Prior art date: 2010-10-27

Application number

LTEP18164175.4T

Other languages

English (en)

Inventor

Gerhard Zugmaier

Dirk Nagorsen

Juergen Scheele

Original Assignee

Amgen Research (Munich) Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-27

Filing date

2011-10-27

Publication date

2020-07-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3412687(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-27 Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh

2020-07-27 Publication of LT3412687T publication Critical patent/LT3412687T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Carbon And Carbon Compounds (AREA)

LTEP18164175.4T 2010-10-27 2011-10-27 Didžiųjų b ląstelių difuzinės limfomos gydymo būdai LT3412687T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40710710P	2010-10-27	2010-10-27

Publications (1)

Publication Number	Publication Date
LT3412687T true LT3412687T (lt)	2020-07-27

Family

ID=45023802

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP15195076.3T LT3018145T (lt)	2010-10-27	2011-10-27	Priemonės ir būdai dlbcl gydymui
LTEP18164175.4T LT3412687T (lt)	2010-10-27	2011-10-27	Didžiųjų b ląstelių difuzinės limfomos gydymo būdai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP15195076.3T LT3018145T (lt)	2010-10-27	2011-10-27	Priemonės ir būdai dlbcl gydymui

Country Status (31)

Country	Link
US (2)	US9192665B2 (lt)
EP (3)	EP3018145B1 (lt)
JP (3)	JP5997168B2 (lt)
KR (1)	KR101889995B1 (lt)
CN (2)	CN105251003B (lt)
AU (1)	AU2011322581B2 (lt)
CA (1)	CA2815119C (lt)
CL (1)	CL2013001138A1 (lt)
CR (1)	CR20130245A (lt)
CY (3)	CY1117155T1 (lt)
DK (3)	DK3412687T3 (lt)
EA (1)	EA032139B1 (lt)
ES (3)	ES2675299T3 (lt)
HK (1)	HK1188229A1 (lt)
HR (2)	HRP20151444T4 (lt)
HU (3)	HUE027678T2 (lt)
IL (3)	IL225924A (lt)
LT (2)	LT3018145T (lt)
MA (1)	MA34619B1 (lt)
ME (1)	ME02311B (lt)
MY (1)	MY163057A (lt)
NZ (2)	NZ701715A (lt)
PL (3)	PL3412687T3 (lt)
PT (3)	PT2632954E (lt)
RS (3)	RS60094B1 (lt)
SG (1)	SG189869A1 (lt)
SI (3)	SI2632954T2 (lt)
SM (1)	SMT201600050B (lt)
TR (1)	TR201808019T4 (lt)
UA (1)	UA111175C2 (lt)
WO (1)	WO2012055961A1 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5129122B2 (ja)	2005-04-26	2013-01-23	トリオンファーマゲーエムベーハー	癌治療のための抗体およびグルココルチコイドの組み合わせ
SG189869A1 (en) *	2010-10-27	2013-06-28	Amgen Res Munich Gmbh	Means and methods for treating dlbcl
CA2816668C (en)	2010-11-10	2021-03-23	Amgen Research (Munich) Gmbh	Prevention of adverse effects caused by cd3 specific binding domains
JO3529B1 (ar) *	2013-02-08	2020-07-05	Amgen Res Munich Gmbh	مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
KR102339240B1 (ko)	2013-10-15	2021-12-15	더 스크립스 리서치 인스티튜트	펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
WO2016154621A1 (en)	2015-03-26	2016-09-29	The California Institute For Biomedical Research	SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en)	2015-04-15	2018-12-05	The California Institute for Biomedical Research	Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3466967A1 (en)	2015-05-18	2019-04-10	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
JP2019532017A (ja)	2016-07-14	2019-11-07	フレッドハッチンソンキャンサーリサーチセンター	がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
CN109715668A (zh)	2016-08-02	2019-05-03	T细胞受体治疗公司	用于使用融合蛋白进行tcr重编程的组合物和方法
PT3445787T (pt)	2016-10-07	2021-03-15	Tcr2 Therapeutics Inc	Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão
KR20230172612A (ko)	2016-10-19	2023-12-22	더 스크립스 리서치 인스티튜트	인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
CN110177803A (zh)	2016-11-22	2019-08-27	T细胞受体治疗公司	用于使用融合蛋白进行tcr重新编程的组合物和方法
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
EP3731850A4 (en)	2017-12-29	2021-12-01	Oncorus, Inc.	ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
US20220023430A1 (en) *	2018-11-13	2022-01-27	Lipoxen Technologies Limited	Glycopolysialylation of blinatumomab
TW202108150A (zh) *	2019-05-03	2021-03-01	美商凱特製藥公司	投與嵌合抗原受體免疫療法之方法
WO2020232247A1 (en)	2019-05-14	2020-11-19	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
WO2022117799A2 (en) *	2020-12-04	2022-06-09	Morphosys Ag	Anti-cd19 combination therapy
JP2024506831A (ja)	2021-01-28	2024-02-15	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	サイトカイン放出症候群を治療するための組成物及び方法
US20230357446A1 (en)	2022-04-11	2023-11-09	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988009344A1 (en)	1987-05-21	1988-12-01	Creative Biomolecules, Inc.	Targeted multifunctional proteins
WO1999054440A1 (en)	1998-04-21	1999-10-28	Micromet Gesellschaft Für Biomedizinische Forschung Mbh	CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1629012B1 (en)	2003-05-31	2018-11-28	Amgen Research (Munich) GmbH	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US10000574B2 (en)	2003-11-28	2018-06-19	Amgen Research (Munich) Gmbh	Compositions comprising polypeptides
CA2597924C (en)	2005-02-15	2018-10-02	Duke University	Anti-cd19 antibodies and uses in oncology
JP5129122B2 (ja) *	2005-04-26	2013-01-23	トリオンファーマゲーエムベーハー	癌治療のための抗体およびグルココルチコイドの組み合わせ
CN101331151A (zh) *	2005-12-16	2008-12-24	麦克罗梅特股份公司	***性疾病的方式和方法
CA2633594C (en) *	2005-12-16	2021-10-26	Micromet Ag	Means and methods for the treatment of tumorous diseases
ATE551071T1 (de)	2006-09-08	2012-04-15	Medimmune Llc	Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
BRPI0809594A2 (pt)	2007-04-03	2019-08-27	Micromet Ag	polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
LT2982696T (lt) *	2008-11-07	2019-06-10	Amgen Research (Munich) Gmbh	Ūmios limfoblastinės leukemijos gydymas
ME02947B (me)	2009-10-27	2018-04-20	Amgen Res Munich Gmbh	Režim doziranja kod primjene dvojno specifičnog protutijela cd19xcd3
SG189869A1 (en) *	2010-10-27	2013-06-28	Amgen Res Munich Gmbh	Means and methods for treating dlbcl

2011
- 2011-10-27 SG SG2013026828A patent/SG189869A1/en unknown
- 2011-10-27 SI SI201130709T patent/SI2632954T2/sl unknown
- 2011-10-27 CN CN201510672546.6A patent/CN105251003B/zh active Active
- 2011-10-27 PL PL18164175T patent/PL3412687T3/pl unknown
- 2011-10-27 MA MA35841A patent/MA34619B1/fr unknown
- 2011-10-27 CA CA2815119A patent/CA2815119C/en active Active
- 2011-10-27 DK DK18164175.4T patent/DK3412687T3/da active
- 2011-10-27 KR KR1020137013384A patent/KR101889995B1/ko active IP Right Grant
- 2011-10-27 PL PL11787633T patent/PL2632954T5/pl unknown
- 2011-10-27 WO PCT/EP2011/068851 patent/WO2012055961A1/en active Application Filing
- 2011-10-27 ES ES15195076.3T patent/ES2675299T3/es active Active
- 2011-10-27 EP EP15195076.3A patent/EP3018145B1/en active Active
- 2011-10-27 SI SI201131489T patent/SI3018145T1/en unknown
- 2011-10-27 UA UAA201306486A patent/UA111175C2/uk unknown
- 2011-10-27 PT PT117876334T patent/PT2632954E/pt unknown
- 2011-10-27 JP JP2013535437A patent/JP5997168B2/ja active Active
- 2011-10-27 NZ NZ701715A patent/NZ701715A/en unknown
- 2011-10-27 LT LTEP15195076.3T patent/LT3018145T/lt unknown
- 2011-10-27 SI SI201131861T patent/SI3412687T1/sl unknown
- 2011-10-27 ES ES18164175T patent/ES2787044T3/es active Active
- 2011-10-27 US US13/881,889 patent/US9192665B2/en active Active
- 2011-10-27 RS RS20200368A patent/RS60094B1/sr unknown
- 2011-10-27 EP EP18164175.4A patent/EP3412687B1/en active Active
- 2011-10-27 LT LTEP18164175.4T patent/LT3412687T/lt unknown
- 2011-10-27 HU HUE11787633A patent/HUE027678T2/en unknown
- 2011-10-27 DK DK11787633.4T patent/DK2632954T4/da active
- 2011-10-27 DK DK15195076.3T patent/DK3018145T3/en active
- 2011-10-27 RS RS20180624A patent/RS57260B1/sr unknown
- 2011-10-27 HU HUE18164175A patent/HUE048639T2/hu unknown
- 2011-10-27 PT PT181641754T patent/PT3412687T/pt unknown
- 2011-10-27 TR TR2018/08019T patent/TR201808019T4/tr unknown
- 2011-10-27 MY MYPI2013001269A patent/MY163057A/en unknown
- 2011-10-27 EP EP11787633.4A patent/EP2632954B2/en active Active
- 2011-10-27 ME MEP-2015-213A patent/ME02311B/me unknown
- 2011-10-27 NZ NZ609201A patent/NZ609201A/en unknown
- 2011-10-27 CN CN201180063222.2A patent/CN103459425B/zh active Active
- 2011-10-27 HU HUE15195076A patent/HUE037786T2/hu unknown
- 2011-10-27 AU AU2011322581A patent/AU2011322581B2/en active Active
- 2011-10-27 RS RS20160027A patent/RS54525B2/sr unknown
- 2011-10-27 PT PT151950763T patent/PT3018145T/pt unknown
- 2011-10-27 PL PL15195076T patent/PL3018145T3/pl unknown
- 2011-10-27 ES ES11787633T patent/ES2563439T5/es active Active
- 2011-10-27 EA EA201390387A patent/EA032139B1/ru not_active IP Right Cessation
2013
- 2013-04-24 IL IL225924A patent/IL225924A/en active IP Right Grant
- 2013-04-25 CL CL2013001138A patent/CL2013001138A1/es unknown
- 2013-05-27 CR CR20130245A patent/CR20130245A/es unknown
2014
- 2014-02-14 HK HK14101399.9A patent/HK1188229A1/xx unknown
2015
- 2015-10-16 US US14/885,404 patent/US10696744B2/en active Active
- 2015-12-31 HR HRP20151444TT patent/HRP20151444T4/hr unknown
2016
- 2016-01-29 CY CY20161100083T patent/CY1117155T1/el unknown
- 2016-02-17 SM SM201600050T patent/SMT201600050B/xx unknown
- 2016-06-01 JP JP2016110083A patent/JP6254220B2/ja active Active
2017
- 2017-11-29 JP JP2017228716A patent/JP6522722B2/ja active Active
- 2017-12-05 IL IL256110A patent/IL256110B/en active IP Right Grant
2018
- 2018-05-16 CY CY20181100508T patent/CY1120227T1/el unknown
- 2018-06-05 HR HRP20180882TT patent/HRP20180882T1/hr unknown
- 2018-07-25 IL IL260774A patent/IL260774B/en active IP Right Grant
2020
- 2020-05-08 CY CY20201100425T patent/CY1123251T1/el unknown

Also Published As

Publication number	Publication date
IL260774B (en)	2019-02-28
IL225924A (en)	2017-12-31
HRP20180882T1 (hr)	2018-07-27
HUE037786T2 (hu)	2018-09-28
CY1123251T1 (el)	2021-10-29
JP2016164192A (ja)	2016-09-08
JP5997168B2 (ja)	2016-09-28
HUE027678T2 (en)	2016-11-28
ES2675299T3 (es)	2018-07-10
EP2632954B2 (en)	2021-07-07
CR20130245A (es)	2013-09-20
ES2563439T5 (es)	2022-02-04
IL225924A0 (en)	2013-06-27
HRP20151444T1 (hr)	2016-01-29
CY1120227T1 (el)	2018-12-12
KR101889995B1 (ko)	2018-08-20
PL3018145T3 (pl)	2018-09-28
UA111175C2 (uk)	2016-04-11
KR20140019298A (ko)	2014-02-14
JP2013540799A (ja)	2013-11-07
EP2632954B1 (en)	2015-11-25
SI2632954T2 (sl)	2021-11-30
PL2632954T5 (pl)	2021-11-02
LT3018145T (lt)	2018-05-10
JP6522722B2 (ja)	2019-05-29
US20130287778A1 (en)	2013-10-31
CN105251003B (zh)	2019-08-02
RS60094B1 (sr)	2020-05-29
RS54525B2 (sr)	2021-08-31
CA2815119A1 (en)	2012-05-03
EA201390387A1 (ru)	2013-10-30
PL3412687T3 (pl)	2020-07-27
IL256110B (en)	2018-08-30
AU2011322581A1 (en)	2013-05-09
US20160208001A1 (en)	2016-07-21
US9192665B2 (en)	2015-11-24
WO2012055961A1 (en)	2012-05-03
NZ701715A (en)	2016-05-27
CY1117155T1 (el)	2017-04-05
ES2563439T3 (es)	2016-03-15
AU2011322581B2 (en)	2015-04-23
ME02311B (me)	2016-06-20
CA2815119C (en)	2023-01-10
JP2018039838A (ja)	2018-03-15
SG189869A1 (en)	2013-06-28
DK2632954T3 (en)	2016-02-01
PL2632954T3 (pl)	2016-05-31
PT3018145T (pt)	2018-05-17
EP2632954A1 (en)	2013-09-04
MA34619B1 (fr)	2013-10-02
CN103459425A (zh)	2013-12-18
CN103459425B (zh)	2015-11-25
PT3412687T (pt)	2020-04-03
DK2632954T4 (da)	2021-08-09
SI3412687T1 (sl)	2020-07-31
HK1188229A1 (en)	2014-04-25
TR201808019T4 (tr)	2018-06-21
DK3412687T3 (da)	2020-05-11
SI3018145T1 (en)	2018-08-31
RS57260B1 (sr)	2018-08-31
EA032139B1 (ru)	2019-04-30
IL256110A (en)	2018-02-28
EP3018145B1 (en)	2018-04-04
EP3412687A1 (en)	2018-12-12
EP3018145A1 (en)	2016-05-11
EP3412687B1 (en)	2020-03-18
SMT201600050B (it)	2016-04-29
NZ719768A (en)	2021-07-30
PT2632954E (pt)	2016-02-03
RS54525B1 (en)	2016-06-30
CL2013001138A1 (es)	2014-11-14
ES2787044T3 (es)	2020-10-14
NZ609201A (en)	2015-01-30
MY163057A (en)	2017-08-15
SI2632954T1 (sl)	2016-02-29
CN105251003A (zh)	2016-01-20
HUE048639T2 (hu)	2020-08-28
DK3018145T3 (en)	2018-05-28
US10696744B2 (en)	2020-06-30
HRP20151444T4 (hr)	2021-08-20
JP6254220B2 (ja)	2017-12-27

Publication	Publication Date	Title
HRP20180882T1 (hr)	2018-07-27	Sredstva za i postupci liječenja dlbcl
EP2558109A4 (en)	2014-09-24	METHOD FOR TREATING HARD TUMORS
EP2611496A4 (en)	2014-01-22	Methods of Treatment
GB201001833D0 (en)	2010-03-24	Method
EP2531625A4 (en)	2014-12-31	PROCESS FOR PROCESSING FRACTURE MATERIALS
PL2526141T3 (pl)	2017-12-29	Sposób obróbki powierzchniowej
HUE037962T2 (hu)	2018-09-28	Eljárás szilárd anyag-folyadék keverékek kezelésére
ZA201208219B (en)	2013-07-31	Method for treating wasterwater
EP2635286A4 (en)	2014-11-12	METHOD FOR THE TREATMENT OF CANCER
IL225623A0 (en)	2013-06-27	Psoriasis treatment methods
IL220594A0 (en)	2012-08-30	Treatment method
GB201004759D0 (en)	2010-05-05	Method
EP2654749A4 (en)	2014-11-12	PROCESS FOR TREATING COPD
GB201006306D0 (en)	2010-06-02	Method
EP2536282A4 (en)	2013-07-03	METHOD FOR THE TREATMENT OF INFECTIONS
HK1209040A1 (en)	2016-03-24	Methods for treating vestibulotoxicity
GB201007207D0 (en)	2010-06-16	Method
GB201005447D0 (en)	2010-05-19	Apparatus for retaining
GB201010317D0 (en)	2010-08-04	Method
GB201005046D0 (en)	2010-05-12	Method
GB201004760D0 (en)	2010-05-05	Method
GB201004169D0 (en)	2010-04-28	Method
GB201001394D0 (en)	2010-03-17	Method
GB201000766D0 (en)	2010-03-03	Method